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Genetic association of long-chain acyl-CoA synthetase 1
variants with fasting glucose, diabetes, and subclinical
atherosclerosis
Ani Manichaikul,*,† Xin-Qun Wang,† Wei Zhao,§ Mary K. Wojczynski,** Kyle Siebenthall,††
John A. Stamatoyannopoulos,†† Danish Saleheen,§,§§,*** Ingrid B. Borecki,**
Muredach P. Reilly,§,††† Stephen S. Rich,* and Karin E. Bornfeldt1,§§§,****

Abstract Long-chain acyl-CoA synthetase 1 (ACSL1) converts
free fatty acids into acyl-CoAs. Mouse studies have revealed
that ACSL1 channels acyl-CoAs to ␤-oxidation, thereby reducing glucose utilization, and is required for diabetesaccelerated atherosclerosis. The role of ACSL1 in humans
is unknown. We therefore examined common variants in the
human ACSL1 locus by genetic association studies for fasting glucose, diabetes status, and preclinical atherosclerosis
by using the MAGIC and DIAGRAM consortia; followed by
analyses in participants from the Multi-Ethnic Study of Atherosclerosis, the Penn-T2D consortium, and a meta-analysis
of subclinical atherosclerosis in African Americans; and finally, expression quantitative trait locus analysis and identification of DNase I hypersensitive sites (DHS). The results
show that three SNPs in ACSL1 (rs7681334, rs735949, and
rs4862423) are associated with fasting glucose or diabetes
status in these large (>200,000 subjects) data sets. Furthermore, rs4862423 is associated with subclinical atherosclerosis and coincides with a DHS highly accessible in human
heart. SNP rs735949 is in strong linkage disequilibrium with
rs745805, significantly associated with ACSL1 levels in skin,
suggesting tissue-specific regulatory mechanisms. This
study provides evidence in humans of ACSL1 SNPs associated with fasting glucose, diabetes, and subclinical atherosclerosis and suggests links among these traits and acyl-CoA
synthesis.—Manichaikul, A., X-Q. Wang, W. Zhao, M. K.
Wojczynski, K. Siebenthall, J. A. Stamatoyannopoulos, D.
Saleheen, I. B. Borecki, M. P. Reilly, S. S. Rich, and K. E.
Bornfeldt. Genetic association of long-chain acyl-CoA synthetase 1 variants with fasting glucose, diabetes, and subclinical atherosclerosis. J. Lipid Res. 2016. 57: 433–442.
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The enzyme long-chain acyl-CoA synthetase 1 (ACSL1),
which catalyzes conversion of free long-chain fatty acids
into their acyl-CoA derivatives, has emerged as a metabolic
rheostat in mouse skeletal muscle, heart, and adipose tissue (1–3). Thus, mice deficient in ACSL1 in skeletal muscle exhibit a marked reduction in fatty acid utilization
through ␤-oxidation and a concomitant increase in glucose utilization during fasting, and they are hypoglycemic
during endurance training (4). In the heart, which relies
heavily on fatty acids as an energy source, ACSL1 deficiency results in reduced fatty acid oxidation and increased
glucose utilization (1, 2). Mice with adipose tissue-selective
ACSL1 deficiency have reduced blood glucose levels during cold exposure (3). Furthermore, an inducible wholebody ACSL1-deficient mouse model exhibits lower blood
glucose levels than matched controls (1). Thus, mouse
studies have revealed a clear relationship between reduced
blood glucose levels and reduced ACSL1 activity in several
tissues due to metabolic flexibility in these tissues.
ACSL1 is ubiquitously expressed, with high levels in typical insulin target tissues, such as skeletal muscle, liver, and
adipose tissue (5). ACSL1 is also expressed in myeloid cells,

Abbreviations: ACSL1, acyl-CoA synthetase 1; CAC, coronary artery calcification; CEU, northern Caucasian Europeans (from Utah);
DHS, DNase I hypersensitive site; DIAGRAM, Diabetes Genetics Replication and Meta-Analysis; eQTL, expression quantitative trait locus;
GWAS, genome-wide association study; MAGIC, Meta-Analyses of Glucose and Insulin-Related Traits Consortium; MAF, minor allele frequency;
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particularly in myeloid cells stimulated with inflammatory
molecules, such as Toll-like receptor (TLR) 4 ligands, Gramnegative bacteria, TLR1/2 ligands, TLR3 ligands, TNF-␣,
and IFN-␥ (6–8). Both in mouse and human macrophages,
plasma membrane-associated ACSL1 levels increase after
TLR4 and IFN-␥ stimulation (6, 9) and also increase in human macrophages exposed to increased metabolic activation by insulin, elevated glucose, and palmitate (10). When
these cells are exposed to metabolic or inflammatory activation, ACSL1 is required for effective phospholipid
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MATERIALS AND METHODS
Candidate association analyses from large-scale consortia
To perform association analysis of common variants within the
ACSL1 gene region, we examined published GWAS and customarray results from the MAGIC and DIAGRAM consortia. We report the SNP demonstrating the strongest association with the
analyzed traits for each study.
MAGIC. MAGIC published a GWAS of fasting glucose and
fasting insulin in up to 46,196 nondiabetic participants of European
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replenishment, neutral lipid accumulation, and early atherosclerosis in the context of diabetes (6, 7, 11). Mice deficient in ACSL1 selectively in myeloid cells or endothelial
cells do not exhibit reduced blood glucose levels (6, 12).
Whereas mouse studies indicate that ACSL1 might play
a critical role in maintaining glucose homeostasis and atherosclerosis, the role of ACSL1 in humans is unknown. Because of the studies discussed above, we were particularly
interested in the relationship between human ACSL1 SNPs
with variation in fasting glucose, diabetes, and risk of atherosclerosis. We interrogated published [Meta-Analyses of
Glucose and Insulin-Related Traits Consortium (MAGIC)
and Diabetes Genetics Replication and Meta-Analysis
(DIAGRAM) consortium] genome-wide association study
(GWAS) scans of fasting glucose (13, 14) and diabetes status (15) with respect to common [minor allele frequency
(MAF) >5%] SNPs in the ACSL1 locus (4q35.1). MAGIC
contains >46,000 healthy nondiabetic individuals of European descent, while DIAGRAM has >56,000 individuals of
primarily European descent (>12,000 with type 2 diabetes). For the common ACSL1 SNPs identified through the
MAGIC and DIAGRAM consortia, we conducted follow-up
analyses of participants with and without diabetes from
the Multi-Ethnic Study of Atherosclerosis (MESA) and in
>200,000 subjects with and without type 2 diabetes included in the Penn-T2D consortium. The analyses in
MESA allowed us to expand discoveries from the published GWAS effort to examine evidence of association a)
across race/ethnic groups and b) with subclinical atherosclerosis traits, and the analysis in the Penn-T2D consortium allowed us to expand our analysis to a much larger
sample size. The association between ACSL1 SNPs and
coronary artery calcification (CAC) was validated in African
Americans (16). Furthermore, expression quantitative trait
locus (eQTL) analysis was used to investigate if the identified ACSL1 SNPs were associated with ACSL1 levels in
skin, lymphocytes, and adipose tissue, and finally, DNase I
hypersensitive sites (DHSs) coinciding with these SNPs
were analyzed in several fetal and adult human tissues.
Together, our results demonstrate that three SNPs in
the ACSL1 gene are associated with markers of fasting glucose or diabetes status and that one of these SNPs is also
significantly associated with subclinical atherosclerosis.
This represents the first indication of ACSL1 contributing
to the regulation of fasting glucose and risk of diabetes
and subclinical atherosclerosis in humans.
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descent in 2010 (13). A subsequent effort from MAGIC performed a GWAS of the same traits with adjustment for BMI in an
expanded sample of up to 51,750 nondiabetic participants of
European descent (14).
DIAGRAM. The DIAGRAM consortium performed a GWAS
of type 2 diabetes in 12,171 cases and 56,862 controls comprising
the DIAGRAM v3 GWAS (15). The SNPs identified through
GWAS contributed to the design of the Metabochip, a custom
genotyping array used for genetic association analysis of type 2
diabetes in an expanded sample of (primarily European descent)
34,840 cases and 114,981 controls.

Analysis of ACSL1 SNPs in MESA
MESA. The MESA is a longitudinal cohort study of subclinical cardiovascular disease and risk factors in 6,814 men and
women 45 to 84 years of age, initially free of overt disease, that
predict progression to disease or progression of subclinical disease (18). The MESA Family Study (MESAFS) recruited 1,595
African American and Hispanic family members 45 to 84 years of
age specifically for genetic analysis, and the MESA Air Pollution
Study recruited an additional 257 participants (19). MESA participants had detailed medical histories and examinations for anthropometry, blood pressure, and vascular imaging [to obtain
measures of subclinical atherosclerosis of CAC and common
(cIMT) and internal carotid intima-media thickness (iIMT)]
(20). Glucose concentrations were determined from fasting samples, and diabetes status was defined using the 2003 American
Diabetes Association fasting criteria (fasting glucose ⭓126 mg/dl)
(21) and/or diabetes treatment. Characterization of MESA
subjects included in the present study is included in the supplementary Materials and supplementary Tables 1 and 2. MESA
participants were genotyped using the Affymetrix Human SNP
array 6.0 (22). Imputation was conducted with IMPUTE v2 using
Phase 1 v3 of the cosmopolitan 1,000 genomes reference set
(23), followed by robust quality control (24).
Genetic association analysis in MESA. MESA participants were
stratified by race/ethnic group using an unrelated subset of individuals from MESA and from MESAFS, by selecting, at most, one
individual from each pedigree, based on inferred relationships
in KING (25). Linear regression of quantitative phenotypes or
logistic regression of dichotomous phenotypes was performed
under an additive 1 d.f. genetic dosage model in R. For phenotypes with a substantial familial component, we performed analysis using linear mixed-effects models for quantitative traits, or
generalized estimating equations for dichotomous traits, to account for familial relationships as implemented in the package
R/GWAF (26). A basic model including age, gender, study site,
and principal components of ancestry was used. Fixed effect
meta-analysis was performed to combine race/ethnic specific results using METAL (27).

Penn-T2D consortium. The Penn-T2D consortium used publicly available DIAGRAM meta-analyses data, updated by adding
additional T2D GWAS/Metabochip studies that have not previously contributed data to the DIAGRAM consortium (findings
from these analyses are currently submitted for publication). The
Penn-T2D consortium consists of data from 56,241 type 2 diabetes cases and 187,815 controls.

Replication and validation in MESA and Penn-T2D for
SNPs identified in consortia studies
For each of the three ACSL1 SNPs identified in MAGIC and
DIAGRAM associated with fasting glucose and diabetes (Table
1), analyses were focused on replicating and validating association with the corresponding trait analyzed in discovery of each
SNP in MESA and the Penn-T2D consortium. Statistical significance for replication of the three SNPs was determined at a Bonferroni-corrected threshold of ␣= 0.05/3 = 0.017, whereas ␣=
0.05 was considered as nominal evidence of replication. For secondary analysis of subclinical atherosclerosis traits in MESA, we
report findings as significant if they reach a Bonferroni-corrected
threshold of ␣= 0.05/12 = 0.0042, corresponding to three SNPs
and four traits, or 12 tests.

Meta-analysis of CAC in African Americans
This study amassed data on 5,823 African Americans from
eight US studies in CAC, examining various definitions of CAC:
ln[CAC+1]; CAC present/absent; ln(CAC) where CAC >0; and
BLOM transformed CAC, defined by Gomez et al. (28). Results
from the eight studies were meta-analyzed in METAL (16). For
this validation study, we used the results from subjects with CAC
>0 on 2,520 subjects. This cohort included African Americans
from MESA (29% of subjects). Statistical significance for replication of the three SNPs was determined at a threshold of ␣= 0.05/
3 = 0.017 after Bonferroni correction.

CARDIoGRAMplusC4D consortium
In order to investigate association of the three identified ACSL1
SNPs with cardiovascular events (myocardial infarction, symptomatic coronary events, or coronary stenosis), we took advantage of
the CARDIoGRAMplusC4D consortium. CARDIoGRAM GWAS is
a meta-analysis of 22 GWASs in participants of European descent
involving 22,233 cases and 64,762 controls, and C4D GWAS is a
meta-analysis of GWASs in participants of European and South
Asian descent involving 15,420 coronary heart disease cases and
15,062 controls. GWAS data from both of these consortia contain
nonoverlapping participants (29). We used this publicly available
data and conducted a fixed-effects meta-analysis yielding a sample
size of 37,653 coronary heart disease cases and 80,182 controls.

Multiple Tissue Human Expression Resource analysis
The Multiple Tissue Human Expression Resource (MuTHER)
consortium data (http://www.muther.ac.uk) were used to investigate if the three identified ACSL1 SNPs were associated with
ACSL1 levels, representing an eQTL analysis. MuTHER contains
genome-wide expression (Illumina HT-12v3 array) profiles on
lymphocytes, subcutaneous fat, and skin biopsies from ⵑ856
twins from the TwinsUK BioResource. MuTHER was interrogated for changes in probe ILMN_1684585 (ACSL1).

ACSL1 variants, diabetes, and atherosclerosis
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Genetic association analysis of ACSL1 variants in MAGIC and
DIAGRAM. We focused on ACSL1 variants within 50 kb of the
ACSL1 gene, using LocusZoom (17) to identify SNPs within the
region from the published GWAS and custom genotyping array
results. We then conducted candidate association analyses for
each of the four selected published data sets, the original MAGIC
GWAS (13), the MAGIC BMI-adjusted GWAS (14), the DIAGRAM v3 GWAS (15), and the DIAGRAM Metabochip (15). For
each lookup, we applied a Bonferroni correction for the number
of SNPs identified within the target region. Here, we report those
SNPs reaching the specified Bonferroni threshold for at least one
of the published data sets.

For each of the three SNPs identified in consortium studies
(Table 1), primary analyses in MESA focused on the phenotype
analyzed in discovery of each SNP, including glucose (log-transformed) and diabetes status. Secondary analysis examined subclinical atherosclerosis (cIMT, iIMT, CAC presence/absence,
and Agatston score for those with CAC >0).

(0.870, 1.25) 0.716
1.04

Each study obtained approval from their respective institutional review board and the ethics committee of each participating
institution, including the University of Alabama at Birmingham,
Washington University, University of Mississippi Medical Center,
University of Minnesota, Northwestern University, Kaiser Permanente (Oakland, CA), University of Washington, Columbia
University, Johns Hopkins School of Medicine, University of California Los Angeles School of Medicine, Wake Forest University
School of Medicine, University of Michigan Health Sciences and
Behavioral Sciences, the Cedars-Sinai Medical Center, the University of Virginia, and the University of Pennsylvania, and informed
consent from participants. All methodology was compliant with
the principles set forth in the Declaration of Helsinki and Title
45, US Code of Federal Regulations, Protection of Human
Subjects.
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Chromatin accessibility data were obtained from public repositories for human cell lines [ENCODE Consortium (30)] as well
as fetal and adult tissues and primary cell lines [Roadmap Epigenomics Consortium (31) and unpublished observations] and
intersected with the three SNPs examined by this work. Transcription factor binding motif locations were determined as described by Vierstra et al. (32).
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RESULTS
ACSL1 association analysis in published results from
MAGIC
After Bonferroni correction (significance threshold ␣=
0.05/173 = 2.9 × 10⫺4) for 173 SNPs within ACSL1 in the
MAGIC GWAS, we identified rs7681334 as significantly associated with fasting glucose (MAF = 0.40, P = 8.4 × 10⫺6;
Fig. 1A and Table 1). After Bonferroni correction (significance threshold of ␣= 0.05/183 = 2.7 × 10⫺4) for 183 SNPs
within ACSL1 in the MAGIC BMI-adjusted GWAS, we identified rs4862423 in addition to rs7681334 as significantly
associated with fasting glucose (MAF = 0.43, P = 4.6 × 10⫺7;
Fig. 1B and Table 1).
ACSL1 association analysis in published results from
DIAGRAM
We identified rs735949 as significantly associated with
diabetes status (MAF = 0.06, P = 7.8 × 10⫺5) after Bonferroni correction for 173 ACSL1 SNPs in the DIAGRAM v3
GWAS. We also identified rs735949 as significantly associated with diabetes status (MAF = 0.06, P = 3.7 × 10⫺6) after
correction for 9 ACSL1 SNPs in the DIAGRAM Metabochip data (Fig. 1C, D and Table 1).
Replication of ACSL1 results identified from consortia
studies in MESA
In combined meta-analysis across race/ethnic groups
for nondiabetic participants from MESA, we identified
nominal (but not Bonferroni-corrected) evidence of replication for the association of ACSL1 rs4862423 with BMIadjusted fasting glucose; further, the observed direction of
effect was consistent with that seen in MAGIC (Table 1;
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TABLE 1. Summary of SNPs identified in the ACSL1 gene region from MAGIC and DIAGRAM
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MESA Resultsb
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P = 0.037). The effect allele (T/C) frequency was 0.350 in
MAGIC European Caucasians and 0.407 in MESA Caucasian participants. The observed effect size and strength of
association for rs4862423 was most notable in MESA African Americans without diabetes compared with other
race/ethnic groups (P = 0.033; supplementary Table 3).
We did not observe additional race/ethnic specific associations for fasting glucose-related SNPs (supplementary Tables 3 and 4). We did not observe statistically significant
evidence of replication for rs7681334 with fasting glucose
or for rs735949 with diabetes status (Table 1 and supplementary Table 5). Thus, these results demonstrate that the
T allele in rs4862423 (T/C) associates significantly with
increased fasting blood glucose levels in MAGIC, with suggestive evidence of replication in MESA.
Replication and validation of ACSL1 SNP associations in
Penn-T2D meta-analyses
In a second study [Penn-T2D meta-analyses (Penn-T2D
Meta) data], which is larger than either of the two consortia used for discovery analysis and the MESA replication
study, we were able to confirm the association of ACSL1
rs735949 with diabetes status. Furthermore, rs7681334,
which was associated with fasting blood glucose in MAGIC
(Table 1) was also significantly associated with diabetes

status in the Penn-T2D Meta (Table 2). The observed direction of effect was consistent with that seen in MAGIC and
DIAGRAM. ACSL1 rs4862423, which was associated with
fasting glucose in the BMI-adjusted MAGIC with suggestive evidence of replication in MESA (Table 1), showed a
suggestive association with diabetes status (P = 0.065) in
the Penn-T2D Meta for which the direction of effect was
consistent with that seen with fasting glucose in MAGIC
and MESA. Thus, the association of ACSL1 rs735949 and
rs7681334 with fasting glucose and diabetes status is replicated in large cohorts. The association of rs4862423 with
fasting glucose was significant in the BMI-adjusted MAGIC
in nondiabetic subjects, yet failed to reach significant association with diabetes status in the Penn-T2D Meta.
ACSL1 SNP association with subclinical atherosclerosis
in MESA
For subclinical atherosclerosis traits, we observed association of ACSL1 rs7681334 with CAC Agatston score
(among participants with CAC >0) in combined metaanalysis across race/ethnic groups (Table 3; P = 0.003).
The association was stronger in participants without diabetes (Table 3; P = 0.001). We further observed association of
rs4862423 with CAC in participants without diabetes (Table 3;
P = 0.002). Race/ethnic stratification provides consistent
ACSL1 variants, diabetes, and atherosclerosis
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Fig. 1. Regional association plots for statistically significant SNPs identified through candidate association studies in ACSL1 in published
results from genetic consortia. SNP rs7681334 association with fasting glucose in the original MAGIC GWAS (A), SNP rs4862423 association
with fasting glucose in the MAGIC BMI-adjusted GWAS (B), SNP rs735949 association with diabetes status in DIAGRAM v3 GWAS (C), and
SNP rs735949 association with diabetes status in DIAGRAM Metabochip (D). The plots are generated using LocusZoom with 1000 Genomes
CEU as the reference for calculating linkage disequilibrium.
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TABLE 2.

Summary of association with type 2 diabetes status of the three identified SNPs in the ACSL1 gene
region from Penn-T2D Meta

SNP ID

Effect Allele

Noneffect Allele

Beta

SE

P

N Case

N Control

A
T
T

G
C
C

0.031
0.069
0.024

0.009
0.014
0.013

6.56E-04
1.02E-06
6.51E-02

56,241
56,241
20,516

187,815
187,815
66,774

rs7681334
rs735949
rs4862423

CAC results in meta-analysis of African Americans
The association of rs4862423 with CAC observed in
MESA African Americans among those with CAC scores >0
was significant in the expanded sample (Table 4). However, the association of rs7681334 with CAC in MESA was
not observed in the African American sample. Furthermore, an association between rs735949 and CAC was observed in the African American sample, but not in MESA
(Tables 3 and 4). Thus, the association of rs4862423 with
subclinical atherosclerosis was consistent between the two
studies. The association of rs735949 and rs7681334 with
CAC appeared to be influenced by other factors.

eQTL analysis
ACSL1 SNPs were analyzed for evidence of eQTLs using
the MuTHER consortium data on three tissues: subcutaneous fat, lymphocytes, and skin. There were no significant associations for any of the three SNPs with probe
ILMN_1684585 (ACSL1). P values for rs7681334 were 0.45
in fat, 0.59 in lymphocytes, and 0.76 in skin. The corresponding P values for rs735949 were 0.13, 0.56, and 0.054,
and for rs4862423, they were 0.35, 0.73, and 0.68 (supplementary Table 9). The most significant SNP associated
with probe ILMN_1684585 in skin biopsies was rs745805
(P = 0.0014), which is in high linkage disequilibrium with
rs735949 (r2 = 0.832 in 1000G pilot 1 CEU; supplementary
Table 9). These results suggest that rs735949 might be associated with ACSL1 expression levels in some tissues.

Analysis of association of ACSL1 SNPs in the
CARDIoGRAMplusC4D consortium
In addition to testing ACSL1 SNPs for association with
diabetes and subclinical atherosclerosis, we determined
whether the ACSL1 SNPs modified risk for clinical end
points (coronary heart disease). In the CARDIoGRAMplusC4D consortium data, there were no significant associations of ACSL1 SNPs rs7681334, rs735949, or rs4862423
with coronary heart disease (supplementary Table 8).
Chromatin accessibility at the ACSL1 locus
The three trait-associated ACSL1 SNPs are located within
the first (rs4862423) and second (rs7681334, rs735949)
introns of the ACSL1 gene. Noncoding GWAS SNPs are
concentrated in regulatory DNA elements, where they
may modulate transcription factor binding (33). Thus, we
asked whether these ACSL1 polymorphisms coincided
with DHSs, which generically indicate transcription factor

TABLE 3.

DISCUSSION
The role of ACSL1 in humans is unknown, although mouse
studies have shown that this enzyme plays an important

Summary of statistically significant genetic association results for Agatston calcium score in MESA
SNP ID

HG 19 Position

Effect/Other
Allele

All participants

rs7681334

185,710,859

A/G

Participants without
diabetes
Participants without
diabetes

rs7681334

185,710,859

A/G

rs4862423

185,726,548

T/C

Group

EAFa

N

Beta

SE

P

0.497/0.450/
0.647/0.944
0.496/0.452/
0.644/0.928
0.407/0.270/
0.499/0.658

3,852

⫺0.126

0.043

0.003

3,172

⫺0.157

0.046

0.001

3,172

⫺0.150

0.048

0.002

Results are presented based on the basic model of genetic association including adjustment for age, gender,
study site, and principal components of ancestry.
a
EAF for MESA shown separately for Caucasian/African American/Hispanic/Chinese participants.
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binding at active regulatory elements (30). ACSL1 utilizes
alternative promoters, which appear to have different levels of tissue selectivity (Fig. 2A). SNP rs4862423 is located
in intron 1 of ACSL1, a region that is highly accessible to
DNase I in fetal heart tissue, and to a lesser extent in other
fetal tissues (Fig. 2B) as well as adult heart, mucosal (gastric and small bowel), pancreatic, and skeletal muscle tissue (data not shown). This site does not appear to be
active in the hepatocyte cell line HepG2 but is accessible
in multiple cultured epithelial and skeletal muscle cell
lines (data not shown). Furthermore, rs4862423 coincides
with a recognition site for RREB1 (ras responsive element
binding protein 1; Fig. 2C). Although rs735949 coincides
with a DHS in primary skin melanocytes (data not shown),
we did not observe regulatory element activity coinciding
with rs7681334 in any of the cell lines and tissues for which
DHS data are available.

directions of effect for both of these ACSL1 SNPs for Caucasian, African American, and Hispanic participants, but
not Chinese participants (supplementary Tables 6 and 7).
In addition, both SNPs showed stronger effects on CAC
in nondiabetics compared with those with diabetes (Cochran’s Q test for heterogeneity, rs7681334, P = 0.12;
rs4862423, P = 0.04).
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TABLE 4.
SNP ID

rs4862423
rs735949
rs7681334

Summary of results on genetic association results for Agatston calcium score in meta-analysis of CAC
among African Americans
HG 19 Position

Effect/Other Allele

EAF

N

Beta

SE

P

185,726,548
185,716,232
185,710,859

T/C
T/C
A/G

0.2448
0.954
0.4555

2,523
2,523
2,523

⫺0.1757
⫺0.343
⫺0.0066

0.0611
0.1322
0.0538

0.004
0.009
0.912

significant association (defined as P < 0.05) was observed
for any of the three SNPs in a large-scale GWAS metaanalysis of BMI (34).
The present study also demonstrates a significant association of rs4862423 with subclinical atherosclerosis,
measured as CAC scores >0 in MESA and in a follow-up
meta-analysis study in African Americans. The directionality of the association was different for fasting glucose
and CAC. Thus, rs4862423 allele T was associated with increased fasting glucose and decreased CAC. The reason
for the difference in directionality is unclear. Analysis of
cardiovascular events in CARDIoGRAMplusC4D did not
show association with the three ACSL1 SNPs. It is possible
that the association occurs only with early atherosclerosis
or with calcification, rather than with more advanced lesions and clinical events. In this context, it is interesting
that ACSL1 in mice is required for early lesions of atherosclerosis, with a less obvious effect on advanced lesions (6).
All three ACSL1 SNPs are located in intronic regions of
ACSL1 (introns 1 and 2), and our studies demonstrate that
the two SNPs most clearly associated with fasting glucose
and diabetes (rs7681334 and rs735949) do not associate
with identified DNase I accessible regions in several cells,
fetal or adult tissues most likely to be relevant for these
phenotypes. However, we show that rs735949 is associated
with a DNase accessible region in primary skin melanocytes. A previous study identified association of rs735949

Fig. 2. Chromatin accessibility at the ACSL1 locus. A: Normalized densities of DNase I cleavages are shown for 14 human fetal tissues, with
the positions of three GWAS SNPs indicated by gray vertical lines. B: Localization of rs4862423 within a DNase I accessible region with the
highest activity in fetal heart. C: Position of SNP (red box) within a binding motif of RREB1 (blue box).
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role as a metabolic rheostat mechanism in several tissues,
and hence, that loss of ACSL1 results in reduced blood
glucose levels due to reduced fatty acid oxidation under
conditions in which excess energy is needed. We demonstrate here that specific SNPs in the ACSL1 gene are
significantly associated with fasting glucose (rs7681334
and rs4862423) or with diabetes status (rs735949) in the
MAGIC and DIAGRAM consortia. We also report evidence
of replication of the association of rs4862423 with fasting
glucose in nondiabetic participants from MESA, and association of both rs7681334 and rs735949 with diabetes
status in Penn-T2D Meta. Although the Penn-based consortium includes the DIAGRAM data, it contains twice the
number of cases included in DIAGRAM. Together, these
four studies make a strong case for significant association
of the three ACSL1 SNPs with fasting glucose and diabetes.
Furthermore, whereas MAGIC and DIAGRAM included
subjects primarily of European descent, MESA includes
subjects of different race/ethnic groups (mostly Caucasian, African American, and Hispanic participants and
a smaller fraction of Chinese participants). The smaller
sample size in MESA (7,847 participants) compared with
the MAGIC and DIAGRAM consortia and Penn-T2D Meta
probably contributed to the lower level of significance and
statistical power. It is unlikely that the association of the
ACSL1 SNPs with glucose levels is significantly confounded
by BMI or adiposity because no nominally statistically
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associated with increased metabolic syndrome risk (41).
A recent study suggested that rs6552828 (located near
rs4862423) might result in differences in ACSL1 expression (42). It is therefore possible that rs4862423 and other
polymorphisms in intron 1 of the ACSL1 gene result in altered expression of ACSL1 in specific tissues.
In summary, our study is the largest to date examining
ACSL1 SNPs in humans, and the first to examine the association between ACSL1 SNPs, fasting glucose, diabetes,
and subclinical atherosclerosis. Our results demonstrate
that three SNPs in the ACSL1 gene are associated with
markers of fasting glucose or diabetes status and that one
of these SNPs is also significantly associated with subclinical atherosclerosis. This represents the first evidence of
ACSL1 association with regulation of fasting glucose and
risk of diabetes and subclinical atherosclerosis in humans
and suggests possible links between these traits and acylCoA synthesis.
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